

## REMARKS

### Status of the Claims

Claims 1, 3-7, 9-11, and 14-19 are pending. Claims 2, 8, 12, and 13 have been canceled without prejudice or disclaimer of the subject matter claimed therein.

Claims 1, 3, 15, 17, and 18 have been amended. Claim 1 has been amended to delete the non-elected compounds. Claim 3 has been amended to correct its dependency. Claims 17 and 18 have been amended to more concisely claim the invention. The amendments to the claims do not introduce prohibited new matter.

### Response to the Restriction Requirement

In response to the Restriction Requirement, Applicants elect with traverse the invention of Group 5, directed to the compound of formula I, wherein "C" in formula I is represented by variable "H".


Applicants respectfully traverse the Restriction Requirement because the inventions of Groups 5, 29, and 53 are linked by a special technical feature. The invention of Group 5 is directed to compounds of formula I, wherein C in formula I is represented by variable H. The invention of Group 29 is directed to methods of using the compounds of Group 5, and the invention of Group 53 is directed to methods of making the compounds of Group 5. Moreover, Applicants respectfully point out that claims 15-18 of Group 29 are directed to pharmaceutical compositions comprising the compound of Group I and not to pharmaceutical methods of making the compound of Group 5 as alleged by the Office Action. Accordingly, the inventions of Groups 5, 29, and 53 are linked by a special technical feature. Therefore, Applicants respectfully submit that the inventions of Groups 5, 29, and 53 (claims 1, 3-7, 9, 11, and 14-19) should be searched and examined together in the present application.

In the event that the Office Action maintains the Restriction Requirement, Applicants reserve the right to pursue the non-elected subject matter in one or more divisional applications.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: **April 17, 2008**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

  
Sally P. Teng  
Registration No. 45,397